FindTrial
Sign In

anti-CD19 CAR-T cells

BIOLOGICAL7 trials

Sponsors

C. Babis Andreadis, Chinese PLA General Hospital, University of Utah, The Children's Hospital of Zhejiang University School of Medicine, Peking University Third Hospital

Conditions

ANCA Associated Vasculitis (AAV)Acute Lymphoblastic LeukemiaBurkitt LymphomaCAR-T Cell TherapyDiffuse Large B Cell LymphomaFollicular LymphomaIdiopathic Inflammatory Myositis (IIM)Inflammatory Myopathies

Phase 1

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
RecruitingNCT04545762
C. Babis AndreadisBurkitt Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma +7
Start: 2020-09-11End: 2026-10-31Target: 36Updated: 2026-06-22
Chidamide Bridging for CAR-T Therapy
RecruitingNCT05370547
Chinese PLA General HospitalNon Hodgkin's Lymphoma
Start: 2022-05-25End: 2025-06-30Target: 120Updated: 2024-03-06
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
RecruitingNCT06227026
University of UtahAcute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
Start: 2024-02-20End: 2028-05-01Target: 10Updated: 2026-08-26
Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic Sclerosis
SuspendedNCT06792344
The Children's Hospital of Zhejiang University School of MedicineSystemic Sclerosis (SSc)
Start: 2025-12-14End: 2028-12-31Target: 12Updated: 2026-09-08
Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
Not yet recruitingNCT06821659
Peking University Third HospitalANCA Associated Vasculitis (AAV), Inflammatory Myopathies, Sjogren Syndrome +2
Start: 2025-03-01End: 2028-12-31Target: 9Updated: 2025-02-12
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS
WithdrawnNCT06842589
The Children's Hospital of Zhejiang University School of MedicineCAR-T Cell Therapy, Multi-Drug Resistant Nephrotic Syndrome
Start: 2025-05-14End: 2028-01-31Updated: 2026-06-16
Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases
Not yet recruitingNCT07544225
Gustave Roussy, Cancer Campus, Grand ParisIdiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA), Sjogren's Disease With Dry Eyes +2
Start: 2026-12-01End: 2043-02-01Target: 6Updated: 2026-09-02